Publication details

Endoluminal radiofrequency ablation of hilarcholangiocarcinoma



Year of publication 2016
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Description Purpose: To prove efficacy of endoluminal radiofrequency ablation in palliative treatment of hilar cholangiocarcinoma. Material and methods: 35 patients with hilar cholangiocarcinoma have been enrolled in a prospective randomised study since 2010. The infiltrative type of cholangiocarcinoma was predominant. 65 non-covered self-expandable metal stents were inserted. In group A (n=18) the endoluminal ablation with a bipolar radiofrequency catheter (EndoHPB; EMcision Ltd., London, UK) was performed 0-48 hours prior to the stent insertion, in group B (n=17) the stent was implanted without a prior ablation. The primary endpoints of the study were to determine the rate of complications, duration of stent patency and survival of patients (Kaplan-Meier analysis). Results: The rate of biochemical pancreatitis, which was resolved in 3 days after stent insertion, was significantly higher in group A. The average primary stent patency was 5.9 and 5.7 months in groups A and B, respectively; 3-month and 6-month stent failure was 0% and 6.1% in group A and 6.3% and 25% in group B. The median survival from the initial drainage was 12.3 (6.7- 20.1) and 12.8 (5.7-14.7) months in groups A and B, respectively. Conclusion: The effect of an endoluminal ablation on patients survival was not proven in the prospective randomised clinical study. However, in the group of patients undergoing ablation there is a tendency of a lower rate of early stent failure. The intervention should be associated with very mild biochemical pancreatitis.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info